GILD vs SNY
Gilead Sciences and Sanofi, both Healthcare
Gilead Sciences is the larger company at $154B against $100B. Over the past year GILD returned +36% against -11% for SNY. The RyuScore puts SNY ahead, 55 against 44 out of 100.
| Figure | GILD | SNY |
|---|---|---|
| Last close | $151 | $40.07 |
| Market cap | $154B | $100B |
| Dividend yield | 2.1% | n/a |
| 1-year return | +36% | -11% |
| 5-year return | +155% | +2.8% |
| RyuScoresector-relative, 1–10 | 44/100 | 55/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Gilead Sciences
Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.
Sanofi
Revenue of $24B in H2 2025, net income $2.0B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.